Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior

Kenneth R. Kaufman, Viwek Bisen, Aphrodite Zimmerman, Anthony Tobia, Ram Mani, Stephen Wong

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Levetiracetam (LEV) is a novel antiepileptic drug (AED) approved for the adjunctive treatment of generalized and partial seizures. LEV has no clinically significant drug interactions and has limited adverse effects. The psychiatric adverse effects of LEV include de novo psychosis, affective disorder, and aggression. LEV-induced suicidal behavior has been reported infrequently with a past history of affective disorders. The authors report an apparent dose/concentration-dependent LEV-induced de novo major depression with near fatal suicide attempt in a patient without prior history of affective disorder. Psychiatric evaluation with emphasis on historic/current affective disorders, impulsive-aggressive behaviors, and assessment of risk factors for suicidal behaviors is indicated in treating patients with epilepsy with LEV. Clinicians should consider therapeutic drug monitoring to optimize therapeutic LEV treatment.

Original languageEnglish (US)
Pages (from-to)110-112
Number of pages3
JournalEpilepsy and Behavior Case Reports
Issue number1
StatePublished - 2013

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience


  • Depression
  • Education
  • Epilepsy
  • Impulsive-aggressive behavior
  • Levetiracetam
  • Psychiatric adverse effect
  • Suicide attempt
  • Therapeutic drug monitoring
  • Traumatic brain injury


Dive into the research topics of 'Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior'. Together they form a unique fingerprint.

Cite this